- Tryp announced its inclusion in the AdvisorShares Psychedelics ETF
- The company hopes that its participation will open it up to a more diverse shareholder base and broaden its life science exposure
- Tryp’s presentation at the KCSA Virtual Investor Conference will also be available for on-demand viewing over the next 90 days
Launched back in September 2021, the AdvisorShares Psychedelics Exchange-Traded Fund (“ETF”) has been actively trading, focusing on enterprises that have devoted a significant proportion of their assets to psychedelic drug development. Operating under the ticker symbol “PSIL” on the New York Stock Exchange (“NYSE”) Arca exchange, this fund has built a portfolio that includes over 25 different psychedelic companies. Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is the latest addition to that group.
Tryp is excited with its inclusion in the fund, particularly since it provides an opportunity to bring a more diverse shareholder base while also broadening life science exposure for the company (https://ibn.fm/8DMHm). Its operations and commitment to developing psilocybin-based compounds for ailments with high unmet medical needs line up with AdvisorShares ETF’s main objective and focus.
Interested parties can now also access Tryp’s KCSA Psychedelics Virtual Investor Conference presentation. In partnership with KCSA Strategic Communications, Virtual Investor Conferences announced that this and other presentations from critical players within the psychedelics space are now available for on-demand viewing (https://ibn.fm/oVNWI).
The two-day event, held on October 13-14, 2021, featured a live overview of Tryp’s activities while elaborating on how it is leading the next wave of psychedelic drug development beyond mental health, focusing on chronic pain and other indications (https://ibn.fm/DcNgu).
These presentations will be available 24/7 over the next 90 days. Interested parties, analysts, investors, and advisors can also download shareholder materials from the company’s “virtual trade booth.”
For those who wish to access the presentations, you can register or log in now at https://ibn.fm/ZQiNc
For more information, visit the company’s website at www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.